Live Analyst Rating Changes 1525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Michael Sarcone
JEF
Michael Sarcone
Jefferies
Wall Street Analyst
★★★☆☆
#814
on 13Foresight · ranked by our own returns
67%
Success Rate
+17.5%
Average Return
6 of 9 calls profitable · +0.9% vs benchmark
🔒 3-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 67% of Michael Sarcone's ratings turned a profit when each position was held for 1 year — averaging +17.5% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

8 Buy 5 Hold 0 Sell
Michael's Stock Coverage 11 ratings · 2026-06-19
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return
AXGN
AxoGen
 Jan 22, 2026 BUY Strong Buy
-25.8% avg upside
21 analysts
$40.00
10.81% Downside
 +39.3%
INSP
Inspire Medical Systems
 Dec 22, 2025 HOLD Buy
+98.0% avg upside
20 analysts
 — -56.8%
GKOS
Glaukos
 Nov 13, 2025 BUY Strong Buy
+5.9% avg upside
20 analysts
$130.00
0.47% Downside
 +56.9%
ALGN
Align Tech
 Oct 10, 2025 HOLD Strong Buy
+58.0% avg upside
21 analysts
$140.00
23.13% Downside
 +38.0%
XRAY
DENTSPLY SIRONA
 Oct 10, 2025 HOLD Buy
+171.7% avg upside
25 analysts
$13.00
25.89% Upside
 -9.4%
PEN
Penumbra
 Jul 23, 2025 BUY Buy
+4.5% avg upside
23 analysts
$325.00
2.50% Upside
 +35.5%
PRCT
PROCEPT BioRobotics
 May 02, 2025 HOLD Buy
+81.6% avg upside
16 analysts
 — -55.7%
FOCL
EDAP TMS
 Apr 03, 2025 HOLD Buy
+43.2% avg upside
7 analysts
$2.00
58.40% Downside
 ·
CH:ALC
Alcon
 Nov 14, 2024 BUY Buy
+34.9% avg upside
35 analysts
$80.49
52.24% Upside
 ·
LMAT
Lemaitre Vascular
 Aug 02, 2023 HOLD Strong Buy
+8.3% avg upside
15 analysts
$67.00
28.65% Downside
 +32.7%
TSE:PRN
Profound Medical
 Mar 21, 2023 HOLD Strong Buy
+97.2% avg upside
11 analysts
$14.14
47.70% Upside
 ·
🔒 6 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Michael Sarcone — Frequently Asked Questions
How accurate are Michael Sarcone's stock ratings?
Based on the calls 13Foresight could measure, about 67% of Michael's ratings were profitable over a one-year hold, with an average return of +17.5% per rating, or +0.9% versus the S&P 500. We score every analyst the same way, from historical prices.
How is Michael ranked on 13Foresight?
Michael Sarcone is currently ranked #814 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Michael cover?
Michael most recently has ratings on AXGN, INSP, GKOS, ALGN, XRAY, PEN, PRCT, FOCL, CH:ALC, LMAT, TSE:PRN. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.